Ensysce Biosciences, Inc.
ENSC
$1.59
$0.031.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -64.04% | 3.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -64.04% | 3.91% | |||
| Cost of Revenue | 53.63% | 2.01% | |||
| Gross Profit | -345.98% | 2.44% | |||
| SG&A Expenses | 6.74% | -14.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.62% | -5.03% | |||
| Operating Income | -113.72% | 11.03% | |||
| Income Before Tax | -115.12% | 10.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -115.12% | 10.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -115.13% | 10.91% | |||
| EBIT | -113.72% | 11.03% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -64.16% | 43.32% | |||
| Normalized Basic EPS | -64.18% | 43.32% | |||
| EPS Diluted | -64.16% | 43.32% | |||
| Normalized Diluted EPS | -64.18% | 43.32% | |||
| Average Basic Shares Outstanding | 31.05% | 57.18% | |||
| Average Diluted Shares Outstanding | 31.05% | 57.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||